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6/j.bHematopoietic stem cell transplantation (HSCT) represents an extended period of physiologic stress. It is
unknown whether patients with pre-existing coronary artery disease (CAD) may be poor transplant can-
didates. There are no data analyzing the risk of transplantation in this population. Sixty-nine patients with
CAD who underwent 72 transplantations, autologous and allogeneic, were identified retrospectively.
Fifty-five percent of these patients had prior percutaneous coronary intervention, 42% had verifiable history
of myocardial infarction, and 23% had prior coronary artery bypass grafting. Outcomes were compared to
1109 patients without established CADwho underwent 1183 transplants during the same time period. Can-
cer diagnoses in the 2 groups were similar, predominantly lymphoma, multiple myeloma, and leukemia.
There was no significant difference between the CAD group and the control group with respect to type
of transplant (autologous 68% versus 64%, P 5 .612, myeloablative 86% versus 85%, P 5 .867).
Treatment-related mortality was no different in the CAD group versus the control group (5.6% versus
4.9%, P 5 .777), nor were there differences in mortality at 1 year (15.3% versus 16.6%, P 5 .871), urgent
intensive care unit admission (11.1% versus 9.9%, P 5 .686), or length of stay (25.5 days versus 28.4 days,
P5 .195). These findings suggest many patients with underlying coronary artery disease may be safely man-
aged through hematopoietic stem cell transplantation.
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Hematopoietic stem cell transplantation (HSCT)
represents an extended period of physiologic stress that
some patients, including those with pre-existing coro-
nary artery disease (CAD), may not tolerate. Histori-
cally, pretransplantation screening, by excluding older
patients, may have excluded patients with CAD. Studies
in the last 10 years havedemonstrated similaroverall sur-
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bmt.2010.12.698(TRM) in older adults who are more likely to have
concurrent CAD [1,2]. Improved outcomes in older
adults are due, in part, to earlier engraftment with
peripheral blood stem cell (PBSC) grafts and improved
supportive care. As a consequence, transplantation
teams are being asked more frequently to assess
patients with CAD as potential candidates for HSCT.
The management of patients with CAD during
HSCT is inherently problematic. They face significant
thrombocytopenia (median 21 days to platelets .50
K), anemia (median transfusions 3, range: 0-30), tachy-
cardia, hypotension, fluid challenges, and electrolyte
imbalance [1]. A significant number of patients are ad-
mitted to the intensive care unit (ICU) (10%-15% of
patients) [1]. Optimal management of these patients
from the cardiac standpoint, including antiplatelet
therapy and beta-blockers, may be precluded.
There are no published data that specifically ad-
dresses the implications of transplanting patients with
concurrent CAD. Mileshkin et al. [1] examined mor-
bidity and mortality during autologous HSCT in
patients aged 60 years or older compared to a younger
cohort. In the older cohort of 40 patients, 5 patients had
CAD, whereas only 2 in the younger cohort had CAD.
Biol Blood Marrow Transplant 17:1182-1186, 2011 1183Retrospective Outcome Data for HSCTThe study reported 50% cardiac toxicity in the older
cohort, including atrial fibrillation, hypotension, or
edema, with no difference in TRM or OS between
the groups, but did not comment on whether the
CAD status of the patients influenced outcomes [1].
The present study aims to systematically quantify the
risk ofHSCTfor patientswithCADas afirst step in de-
termining optimal management for these patients in
the peritransplantation setting.PATIENTS AND METHODS
Patients
Data collection and analysis were performed with
the approval of the Institutional Review Board of
Memorial Sloan-Kettering Cancer Center, New
York, NY. Protected health information was coded
in accordance with requirements of the Health Insur-
ance Portability and Accountability Act. Baseline de-
mographic, clinical, and laboratory data including
cardiovascular risk factors, cancer diagnosis, and
transplant characteristics were collected by a retro-
spective review of the medical records of all patients
who underwent autologous or allogeneic stem cell
transplantation between January 1999 and August
2009. Only patients 40 years or older were included
in the analysis. All patients underwent a clinical assess-
ment of cardiac function prior to transplant, as well as
quantitative assessment of left ventricular ejection
fraction (LV EF) by echocardiography or multiple
gated cardiac blood pool imaging (MUGA). In gen-
eral, patients had LV EF of $50% prior to transplan-
tation. Stress tests were often, but not routinely,
performed and may have been done by the transplant
team as part of the screening process, or may have
been done routinely or for symptoms by an outside
cardiologist with results that were felt to be within
a reasonable time frame of transplantation (usually
1-2 years). During transplantation, patients with
CAD were routinely taken off beta-blockers, statins,
and antiplatelet agents, including aspirin and clopi-
dogrel. Transplant admissions were analyzed for
length of hospital stay, urgent ICU admission, in-
hospital death, death at 1 year, and cardiac complica-
tions during transplantation.Preparative Regimens, Donors, and Grafts
Regimens were identified as myeloablative versus
nonmyeloablative. Total-body irradiation (TBI)
\500 cGy was considered nonmyeloablative. PBSC
grafts for use in autologous stem cell transplantation
were generally obtained by administration of chemo-
therapy followed by granulocyte-colony stimulating
factor (G-CSF) with apheresis on the fifth and, if
needed, the sixth day. A small percentage of patientsunderwent bone marrow (BM) transplantation. Do-
nors for allogeneic stem cell transplantation included
matched/mismatched siblings or unrelated donors re-
cruited via the National Marrow Donor Program.
Slightly more than half of the grafts for allogeneic
transplantation were T cell depleted (TCD). Selection
of CD341 stem cells from PBSC grafts was accom-
plished using the ISOLEX 300iMagnetic Cell Separa-
tor (Baxter labs, Deerfield IL), followed by sheep red
blood cell (sRBC)-rosette depletion of T cells as previ-
ously described [3]. BMTCDwas accomplished by se-
quential soybean agglutination and sRBC-rosette
depletion. For TCD grafts, no medicinal graft-
versus-host disease (GVHD) prophylaxis was given.
Coronary Artery Disease
Manual reviewof eachpatient’s chartwas performed
by a board-certified cardiologist (W.S.). A history of
CAD was defined as$1 of the following: percutaneous
coronary revascularization (PCI), coronary artery by-
pass grafting surgery (CABG), obstructiveCAD(usually
.70% stenosis by cardiac catheterization or.50% ste-
nosis by CT angiogram), ischemia by stress testing, or
documented history of myocardial infarction (MI). Ma-
jor cardiovascular risk factors were identified, including
hypertension, hypercholesterolemia, diabetes, and past
or present cigarette use. Cardiac complications during
the transplantation were identified as symptomatic ar-
rhythmias (atrial fibrillation or atrial flutter with a rapid
ventricular rate, supraventricular tachycardias, or sus-
tained ventricular tachycardia), MI (ST-elevation MI,
non–ST-elevation MI, or troponin elevation), or new
cardiomyopathy. Congestive heart failure was not in-
cluded in this retrospective analysis because of lack of
uniform documentation in the medical record. Trans-
plant course and outcome were compared between pa-
tients with CAD and those without (control group).
All statistical analyses were performed using SAS
9.1 (SAS, SAS Institute, Cary, NC). Continuous vari-
ables were compared using the t-test, and reported
with a standard deviation. Fisher’s exact test was used
to compare categoric variables. P values \.05 were
considered significant.RESULTS
Eleven hundred seventy-eight patients who under-
went a total of 1255 HSCTs were included in the anal-
ysis. Table 1 lists the demographics for the 2 groups.
CAD was confirmed in 69 patients who received 72
transplants. The percentage of male patients in the
CAD group was significantly higher than in the con-
trol group (87.0% versus 57.8%, P\ .0001). The me-
dian age at transplantation was also significantly older
in the CAD group than in the control group (62.19
years versus 55.30 years, P \ .0001). There was no
Table 1. CAD Status and Background Characterization for
Patients Undergoing Transplant
CAD (%) Control (%) P Value
Number of patients 69 1109
Number of transplants 72 1183
Male patients 60 (87.0) 641 (57.8) <.001
Age at transplant ± SD (years) 62.19 ± 5.70 55.30 ± 8.21 <.001
CAD indicates coronary artery disease.
Table 3. Chemotherapy Regimens for CAD Patients and for
Controls Undergoing HSCT
CAD (%) Control (%) P Value
Peripheral blood stem cell
transplantation
71 (98.6) 1146 (96.9) .720
Bone marrow transplantation 1 (1.4) 37 (3.1) .720
Non-myeloablative 10 (13.9) 184 (15.6) .867
Myeloablative 62 (86.1) 999 (84.5) .867
Autologous 49 (68.1) 761 (64.3) .612
Allogeneic 23 (31.9) 422 (35.7) .612
Allogeneic T cell depleted 15 (65.2) 222 (52.6) .286
Allogeneic unmodified 8 (34.8) 200 (47.4) .286
CAD indicates coronary artery disease; HSCT, hematopoietic stem cell
transplantation.
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groups with respect to cancer diagnosis, or the type
of transplant (myeloablative versus nonmyeloablative,
autologous versus allogeneic, PBSC versus bone mar-
row, TCD versus unmodified) (Tables 2 and 3).
Of the 69 patients with CAD, 42.0% had a history
of MI, 55.1% had previously undergone PCI, and
23.2% had a history of CABG (Table 4). Less than
9% of patients had CAD based on stress test results
alone, without verifiable history ofMI or revasculariza-
tion. Forty-three of the patients with CAD had recent
stress tests available on first evaluation for transplant
or as part of the pretransplant screening process. Of
those with stress tests, 30% had evidence of ischemia.
Table 5 describes the proportion of patients in the
CAD and control groups with cardiovascular risk fac-
tors. Diabetes and hypercholesterolemia were more
prevalent in the CAD group than in the controls,
20.3% versus 8.7% (P 5 .004) and 56.5% versus
23.1% (P\ .001), respectively. Smoking history and
hypertension were not significantly different between
the 2 groups.
Outcomes of the transplantation for both groups
are provided in Table 6. There was no difference be-
tween the 2 groups in terms of TRM or mortality at
1 year. Notably, none of the 4 transplant-related
deaths in the CAD group were cardiac in origin. In
the control group, there were 2 ST-elevation MIs in
patients transferred to the ICU with sepsis and multi-
organ failure. Both of these patients died during trans-
plant hospitalization. Rates of urgent admission to the
ICU and lengths of stay were not significantly different
between the 2 groups.
Finally, there was no significant difference between
the 2 groups with respect to the predefined cardiacTable 2. Transplant Cancer Diagnoses of CAD Patients and
Control
CAD (%) Control (%) P Value
Leukemia 14 (19.4) 234 (19.6) 1.000
Lymphoma 23 (31.9) 417 (35.3) .613
Multiple myeloma or
Waldenstrom’s
23 (31.9) 351 (29.6) .691
Myelodysplastic syndrome
or aplastic anemia
4 (5.6) 68 (5.7) 1.000
Amyloid 6 (8.3) 96 (8.1) .827
Other (including testicular cancer
and oligodendroglioma)
2 (2.8) 17 (1.4) .298
CAD indicates coronary artery disease.events, including symptomatic arrhythmias, ST-
elevationMI, non–ST-elevationMI, troponin elevation,
or new cardiomyopathy, although there was a trend to-
ward significance. The cardiac events in both groups
were predominantly atrial arrhythmias, most commonly
atrial fibrillation. In the CAD group, 6 of the 7 cardiac
events identifiedwere atrial arrhythmiaswith rapid rates.
One patient in the CAD group, who had a low-normal
LVEFprior totransplantation,developedacardiomyop-
athy. This patient survived the transplantation. There
were no MIs or troponin elevations in the patients with
pre-existing CAD. In the control group, 6 patients expe-
rienced new cardiomyopathies, 1 in the setting of multi-
organ failure with subsequent in-hospital death. Three
patients developed MIs, 2 ST-elevation myocardial in-
farctions, and 1 non–ST-elevation. The remaining
events were atrial arrhythmias with rapid ventricular
rates.DISCUSSION
This study is the first to systematically investigate
the risk of HSCT for patients with known CAD. Base-
line characteristics between the control and CAD
groups differed as expected. Patients in the CAD
group were more often male, older in age, and had
a higher prevalence of diabetes and hypercholesterol-
emia than those in the control group. Very likely,
a better-powered study would demonstrate a higher
prevalence of cigarette smoking and of hypertension
in the CAD group, as well.Table 4. CAD Characterization for All Confirmed CAD
Patients
CAD Characterization Number of Patients (%)
Myocardial infarction 29 (42.0)
Percutaneous coronary intervention 38 (55.1)
CABG 16 (23.2)
Ischemia on stress testing 13 (18.8)
CAD by stress testing only 6 (8.70)
CAD indicates coronary artery disease; CABG, coronary artery bypass
grafting surgery.
Table 5. Proportion of Comorbidities between CAD and
Control Groups
Comorbidities CAD (%) Control (%) P Value
Diabetes 14 (20.3) 97 (8.7) .004
Hypercholesterolemia 39 (56.5) 256 (23.1) <.001
Smoking 37 (53.6) 467 (42.1) .078
Hypertension 29 (42.0) 377 (34.0) .192
CAD indicates coronary artery disease.
Table 6. Outcomes of HSCT for CAD and Control Groups
Variable CAD (%) Control (%) P Value
Death during transplantation 4 (5.6) 58 (4.9) .777
Death to 1 year 11 (15.3) 196 (16.6) .871
ICU admission 8 (11.1) 117 (9.9) .686
Length of stay ± SD (years) 25.53 ± 11.18 28.42 ± 18.72 .195
Cardiac events 7 (9.7) 59 (5.0) .096
CAD indicates coronary artery disease; HSCT, hematopoietic stem cell
transplantation; ICU, intensive care unit.
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cancer diagnoses, most frequently lymphoma, multiple
myeloma, and leukemia. There was no difference with
respect to source of the graft, predominantly PBSC in
both groups. For patients undergoing allogeneic trans-
plantation, slightly more than half of patients in each
group underwent TCD transplants, as per the standard
practice at this institution. Patients with CAD were
treated as frequently with autologous HSCT or with
myeloablative allogeneic transplant as patients in the
control group.This is reassuring that, at least at this cen-
ter, during the years that were analyzed, patients with
CAD were not routinely undertreated.
The findings that patients with CAD did not have
increased TRM, transplant length of stay, ICU admis-
sion during transplant, or mortality at 1 year suggest
that patients with CAD should not be routinely denied
this potentially life-saving therapy. The trend toward
significance with respect to the predefined cardiovascu-
lar events is not surprising. Likely, a better-powered
studywoulddemonstrate an increased incidenceof these
events in patients with concurrent CAD. Although the
number of events in both groups is small, it is reassuring
that therewerenoMIs in theCADgroup.This is despite
the fact that patients with coronary artery disease were
routinely taken off beta-blockers, statins, and antiplate-
let agents, including aspirin and clopidogrel, for the du-
ration of transplantation. Chart review did not reveal
anysystematicmanagementstrategies, suchasadifferent
transfusion threshold, for patients with CAD compared
to those without.
In comparison to the study of Mileshkin et al. [1],
the age of patients with CAD was slightly younger
than in the older cohort in the prior study, where pa-
tients were stratified by age alone, cutoff age \60.
TRM was slightly lower in the current study (5.6%
in the current study compared to 8% in the older
cohort in the prior study). Admission rates to the
ICU were similar to the ICU admission rates in the
younger cohort in the prior study and slightly lower
when compared to the cohort age 60 or greater (11%
versus 15%). In the prior study, 22% of patients 60
years of age or older experienced atrial fibrillation,
somewhat higher than rates found in Sirohi et al.
[1,2], where atrial fibrillation was identified in 11%
of both the younger and the older cohorts (although
this is accounted for by only 2 patients in each studyarm). In the current study, 8.3% of patients in the
CAD group experienced atrial fibrillation with
a rapid ventricular response, compared to 4.2% of
patients without CAD. The rates of pre-existing
atrial fibrillation were not analyzed.
In general, the patients in the current study had
normal LV EF prior to transplantation. There are 2
papers in the literature that specifically address out-
comes of patients with reduced LV EF in the trans-
plant setting [4,5]. In the study by Muzaffar et al. [4],
15/97 patients with normal LV function and with at
least 1 cardiac risk factor (defined as smoking, hyper-
tension, hyperlipidemia, coronary artery disease, ar-
rhythmia, MI, or congestive heart failure) had
a cardiac complication with transplantation (defined
as arrhythmia, congestive heart failure or cardiac is-
chemia). This was higher than in patients with normal
LV EF and no cardiac risk factors [4]. These findings
do not specifically contradict our findings, as it is un-
clear which of the cardiac risk factors cited above con-
tribute this additional risk [4].
This study is limited in that it is a single-center,
retrospective study. There is significant selection bias
in the pretransplant screening process, which included
a routine evaluation of LV EF, and in the referral pat-
terns to transplantation. Likely, patients with a large
ischemic burden, and/or significantly reduced left ven-
tricular function, uncontrolled arrhythmias, recent
myocardial infarction, or significant anginal symptoms
were not referred for transplantation or were deferred
after routine pretransplant screening.
With these caveats, this study is an important first
step in that it begins the process both of quantifying
and of qualifying the risk ofHSCT for patients with con-
current CAD. The findings presented here suggest that
many patients with CAD can safely be managed through
the peritransplantation period. Prospective studies to
identify appropriate selection criteria for patients with
CAD who may benefit from transplant, as well as to de-
sign effective peritransplant management strategies for
these patients, may be helpful.ACKNOWLEDGMENTS
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